ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
BeOne Medicines Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$370.17+1.11 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $557.24B
- P/E (TTM)
- 860.9
- Dividend yield
- –
BeOne Medicines statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Market Cap | $42.09B | $164.85M |
| Enterprise Value | $38.14B | $87.06M |
| PE Ratio | 66.22 | 19.63 |
| PS Ratio | 6.87 | 3.60 |
| PB Ratio | 8.13 | 2.03 |
| P/TBV Ratio | 8.23 | 2.31 |
| P/FCF Ratio | 31.64 | 17.44 |
| P/OCF Ratio | 28.36 | 13.32 |
Enterprise value
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| EV / Sales | 6.22 | 2.43 |
| EV / EBITDA | 35.38 | 14.69 |
| EV / EBIT | 41.31 | 18.47 |
| EV / FCF | 28.67 | 20.97 |
Income (trailing twelve months)
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Revenue | $6.13B | $57.94M |
| Gross Profit | $5.45B | $90.47M |
| Operating Income | $923.10M | -$21.44M |
| Pretax Income | $868.08M | -$14.45M |
| Net Income | $655.71M | -$22.46M |
| EBITDA | $1.08B | -$16.91M |
| EPS (Diluted) | $0.43 | -$0.83 |
Margins
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Gross Margin | 88.9% | 52.3% |
| Operating Margin | 15.1% | -44.5% |
| Pretax Margin | 14.2% | -13.0% |
| Profit Margin | 10.7% | -39.2% |
| EBITDA Margin | 17.6% | -31.3% |
| FCF Margin | 21.7% | -8.85% |
Returns
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Return on Equity (ROE) | 14.7% | -53.1% |
| Return on Assets (ROA) | 8.47% | -41.0% |
| Return on Invested Capital (ROIC) | 43.7% | -32.0% |
| Return on Capital Employed (ROCE) | 13.1% | -37.8% |
Growth
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 34.3% | 6.01% |
| FCF Growth (YoY) | 443.3% | 2.34% |
| Revenue Growth (3Y CAGR) | 55.7% | 2.25% |
| Revenue Growth (5Y CAGR) | 76.8% | 6.42% |
Balance sheet
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.10B | $62.42M |
| Total Debt | $1.14B | $120.13M |
| Net Cash (Debt) | $3.95B | $15.68M |
| Net Cash Per Share | $2.67 | $0.66 |
| Equity (Book Value) | $5.17B | $48.79M |
| Book Value Per Share | $3.50 | $1.36 |
| Tangible Book Value | $5.11B | $23.06M |
| Working Capital | $5.10B | $75.77M |
Financial position
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Current Ratio | 3.40 | 3.30 |
| Quick Ratio | 2.90 | 2.39 |
| Debt / Equity | 0.22 | 0.51 |
| Debt / EBITDA | 1.06 | 3.35 |
| Debt / FCF | 0.86 | 5.05 |
| Net Debt / EBITDA | -3.67 | 2.22 |
| Interest Coverage | 8.72 | -7.12 |
Cash flow (trailing twelve months)
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Operating Cash Flow | $1.48B | -$12.35M |
| Capital Expenditures | -$153.87M | -$1.06M |
| Free Cash Flow | $1.33B | -$20.28M |
| FCF Per Share | $0.90 | -$0.42 |
Efficiency
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Asset Turnover | 0.79 | 0.38 |
| Inventory Turnover | 1.10 | 2.67 |
| Revenue Per Employee | $510.75K | $398.96K |
| Profits Per Employee | $54.64K | -$703.34K |
| Employee Count | 12,000 | 74 |
Dividends and yields
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Earnings Yield | 1.56% | -22.7% |
| FCF Yield | 3.16% | -9.07% |
Shares
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Shares Outstanding | 1,478,120,000 | 58,179,650 |
| Shares Change (YoY) | 5.73% | 11.1% |
| Shares Change (QoQ) | 1.72% | 0.54% |
| Float | 1,272,610,000 | 49,173,100 |
| Shares Held by Insiders | 13.9% | 11.6% |
| Shares Held by Institutions | 2.37% | 59.4% |
Taxes
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Income Tax | $212.37M | $91.50K |
| Effective Tax Rate | 24.5% | 20.6% |
Scores
| Measure | BeOne Medicines | Industry median |
|---|---|---|
| Graham Number | $5.82 | $17.36 |
| Graham Upside | -79.6% | -43.6% |
| Altman Z-Score | 6.78 | -0.24 |
| Piotroski F-Score | 7 | 4 |
| Beneish M-Score | -2.73 | -2.62 |
Calculated by StockData from BeOne Medicines's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.